SAKAR - Sakar Healthcare
📢 Recent Corporate Announcements
Sakar Healthcare reported a robust 62% YoY revenue growth to ₹70.34 crore for Q3 FY26, driven primarily by its high-margin oncology vertical. Net profit jumped 126% to ₹10.25 crore, supported by operational leverage and a shift toward own-brand exports which now contribute over 70% of revenue. The company has secured 11 marketing authorizations for oncology products in Europe and emerging markets, including Imatinib and Capecitabine. Management has provided a strong outlook, expecting 60-70% growth in the oncology segment for FY27 as more products enter commercialization in regulated markets.
- Revenue from operations grew 62% YoY to ₹70.34 crore in Q3 FY26.
- Profit After Tax (PAT) increased by 126% YoY to ₹10.25 crore with EBITDA margins at 26%.
- Oncology segment contributed ₹31 crore to Q3 revenue, with ₹19 crore derived from exports.
- Received 11 marketing authorizations for oncology products; 10 molecules are currently in tech transfer with Intas/Accord for the EU market.
- Management guides for a 60-70% year-on-year growth in the oncology vertical for FY27.
Sakar Healthcare Limited has officially released the audio recording of its conference call held on February 11, 2026, regarding the Q3FY26 financial results. The call addressed the company's unaudited performance for the quarter and nine-month period ending December 31, 2025. This disclosure is part of the mandatory compliance under SEBI Regulation 30. Investors can now access the management's commentary on business performance directly through the provided link on the company's website.
- Audio recording of the Q3FY26 earnings call is now available on the company's website.
- The call discussed financial results for the quarter and nine months ended December 31, 2025.
- Compliance update filed under Regulation 30 of SEBI (LODR) Regulations, 2015.
- A written transcript of the investor conference call will be shared with exchanges in due course.
Sakar Healthcare is transitioning from a contract manufacturer to a vertically integrated oncology specialist with its EU-GMP certified facility in Bavla, Gujarat. The company has developed 55 oncology molecules, with 32 ready for global launch and 11 Marketing Authorizations already granted. Management highlights that oncology formulations offer approximately 2x higher margins compared to general formulations. The strategic roadmap focuses on increasing own-brand exports to 70% of revenue to enhance long-term profitability and brand equity.
- Developed 55 oncology molecules with 32 ready for launch and 11 Marketing Authorizations granted globally.
- Oncology segment delivers approximately 2x higher margins versus general pharmaceutical formulations.
- Annual production capacity includes 12.3 MT of APIs, 97 million tablets, and 13 million sterile injectable vials.
- Strategic shift targeting 70% of revenue from own-brand exports across 60+ countries.
- EU-GMP approved Bavla facility enables vertical integration from API to Finished Dosage Form (FDF).
Sakar Healthcare Limited has announced a conference call for analysts and institutional investors scheduled for February 11, 2026, at 11:30 AM IST. The call is being held in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such meetings typically involve discussions on the company's financial performance, operational updates, and future growth strategies. Investors should look for the subsequent filing of the call transcript for detailed insights into management's outlook.
- Conference call scheduled for Wednesday, February 11, 2026, at 11:30 AM IST
- Compliance with SEBI (LODR) Regulations, 2015, specifically Regulation 30(6)
- Intimation provided to the National Stock Exchange (NSE) on February 7, 2026
- The schedule is subject to change due to exigencies on the part of participants or the company
Sakar Healthcare reported a stellar Q3 FY26 with revenue growing 62% YoY to ₹7,034 lakhs, driven by its oncology division and EU market demand. Net profit more than doubled, rising 126% YoY to ₹1,025 lakhs, as PAT margins expanded significantly from 10% to 15%. The company's oncology facility received approval as a manufacturing source for Accord Healthcare UK, marking a major milestone for EU exports. With 11 marketing authorizations already secured and over 40 contract discussions ongoing, the company expects accelerated growth in FY27.
- Q3 FY26 Revenue grew 62% YoY to ₹7,034 lakhs, while 9M FY26 Revenue rose 42% to ₹18,064 lakhs
- Net Profit (PAT) for the quarter surged 126% YoY to ₹1,025 lakhs with margins expanding from 10% to 15%
- EBITDA increased 58% YoY to ₹1,859 lakhs, maintaining a healthy margin of 26%
- Secured 11 Marketing Authorizations globally and completed over 50 business contracts for oncology products
- Approved as a manufacturing source for Accord Healthcare UK for Imatinib supplies to the EU market
Sakar Healthcare Limited has scheduled a conference call for analysts and institutional investors on February 11, 2026, at 11:30 AM IST. The company officially notified the National Stock Exchange on February 7, 2026, in compliance with SEBI (LODR) Regulations. These calls typically serve as a platform for management to discuss recent performance and future outlook. Investors should look for the subsequent transcript to gauge management's sentiment and strategic direction.
- Conference call scheduled for Wednesday, February 11, 2026, at 11:30 AM IST
- Intimation filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- The meeting is intended for analysts and institutional investors to discuss company updates
- Notification issued to the National Stock Exchange on February 7, 2026
Sakar Healthcare reported a stellar performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 62% YoY to ₹70.34 crore. Net profit for the quarter more than doubled, reaching ₹10.25 crore compared to ₹4.53 crore in the same period last year. The company's 9-month profit of ₹19.46 crore has already surpassed the full-year FY25 profit of ₹17.50 crore. Operating margins improved significantly, reflected in the EPS jumping from ₹2.08 to ₹4.59 YoY.
- Revenue from operations grew 62% YoY to ₹70.34 crore in Q3 FY26 compared to ₹43.42 crore in Q3 FY25.
- Net Profit surged 126% YoY to ₹10.25 crore, with a strong sequential (QoQ) growth of 125%.
- 9M FY26 Net Profit reached ₹19.46 crore, already exceeding the entire FY25 full-year profit of ₹17.50 crore.
- Basic EPS for the quarter increased significantly to ₹4.59 from ₹2.08 in the year-ago quarter.
- Total expenses for the quarter stood at ₹59.90 crore, driven primarily by material costs of ₹38.54 crore.
Sakar Healthcare reported a robust performance for Q3 FY2025-26, with revenue from operations growing 62% YoY to ₹70.34 crore. Net profit (PAT) saw a significant jump of 126% YoY, reaching ₹10.25 crore compared to ₹4.53 crore in the same quarter last year. On a sequential basis, PAT more than doubled from ₹4.54 crore in Q2 FY26, indicating strong operational momentum. The company's 9-month total income of ₹182.75 crore has already surpassed the full-year income of FY2024-25.
- Revenue from operations increased by 62% YoY to ₹7034.24 lakh from ₹4341.71 lakh.
- Net Profit (PAT) surged by 126% YoY to ₹1024.91 lakh.
- Profit Before Tax (PBT) grew by 100% YoY to ₹1095.25 lakh.
- Basic EPS improved significantly to ₹4.59 from ₹2.08 in the previous year's quarter.
- Total income for the 9-month period reached ₹182.75 crore, exceeding the full FY25 audited income of ₹178.90 crore.
Sakar Healthcare Limited has scheduled a board meeting for February 5, 2026, to consider and approve the unaudited financial results for the quarter ended December 31, 2025. The meeting will review both standalone and consolidated financial statements for the period. In line with SEBI regulations, the trading window for designated persons will remain closed until 48 hours after the results are declared. This is a routine but critical meeting for shareholders to assess the company's mid-year fiscal performance.
- Board meeting scheduled for February 5, 2026, to approve Q3 results.
- Covers unaudited financial results for the quarter ended December 31, 2025.
- Includes both Standalone and Consolidated financial statements.
- Trading window remains closed for designated persons until 48 hours post-announcement.
Sakar Healthcare Limited has responded to a clarification sought by the National Stock Exchange regarding its financial results for the quarter ended September 30, 2025. The exchange questioned the identical nature of standalone and consolidated figures and the reporting format. The company clarified that the figures are identical because its subsidiary company did not conduct any business transactions during the reporting period. Furthermore, the company asserted that its filings are in full compliance with Schedule III of the Companies Act and Indian Accounting Standards.
- Clarification provided for financial results submitted for the quarter ended 30-Sep-2025
- Identical standalone and consolidated figures attributed to zero business transactions in the subsidiary
- Company confirms adherence to Schedule III of the Companies Act, 2013 and Ind AS
- Response follows an NSE query dated January 12, 2026, regarding reporting formats
Sakar Healthcare Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms that securities received for dematerialization during the quarter ended December 31, 2025, were processed correctly. It verifies that security certificates were mutilated and cancelled after due verification and the name of the depositories substituted in the register of members. This is a standard procedural filing required by all listed companies in India.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Issued by Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
- Confirms dematerialization requests were processed within prescribed SEBI timelines.
- Verification that physical security certificates were mutilated and cancelled post-dematerialization.
- Ensures the company is in compliance with depository and participant regulations.
Sakar Healthcare Limited has officially notified the exchange regarding the closure of its trading window starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent insider trading ahead of financial disclosures. The window will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ending December 31, 2025. This is a standard regulatory procedure for all listed companies in India.
- Trading window closure effective from January 1, 2026.
- Closure pertains to the declaration of unaudited financial results for the quarter ending December 31, 2025.
- Window to reopen 48 hours after the results are officially announced to the exchange.
- Compliant with SEBI (Prohibition of Insider Trading) Regulations and NSE Circular No. NSE/CML/2019/11.
Sakar Healthcare's oncology facility has been approved by the European Medical Agency (EMA) as a manufacturing source for Accord Healthcare's Imatinib (100mg and 400mg) tablets. This approval allows Sakar to cater to the European market, marking the first of nine oncology products planned under the Accord partnership. The company anticipates a positive impact on top-line sales in the upcoming fiscal year due to improved capacity utilization. Sakar is now positioned to supply a total of 12 approved products to international markets.
- EMA approval secured for manufacturing Imatinib 100mg and 400mg film-coated tablets for the EU market.
- First of 9 oncology products to be manufactured for Accord Healthcare's European distribution.
- Expected to drive top-line sales growth in the coming fiscal year through higher capacity utilization.
- Sakar now has a portfolio of 12 approved products ready for overseas supply.
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 16% YoY in FY25 to INR 177.58 Cr, with the oncology segment being the primary driver, showing an 80% increase in revenue. In H1 FY26, revenue reached INR 110.30 Cr, a 31.4% increase YoY, driven by continued oncology scale-up.
Geographic Revenue Split
The company exports to 60+ countries across APAC, Latin America, Africa, CIS, and Europe. While specific regional percentages are not disclosed, own-brand exports are identified as a high-margin growth driver.
Profitability Margins
Net Profit Margin improved from 7.61% in FY24 to 10% in FY25. Gross Profit Margin remained stable at 46% in H1 FY26. Return on Net Worth improved from 4.45% to 6.13% in FY25 due to improved PAT of INR 17.50 Cr (up 50% YoY).
EBITDA Margin
Operating margins improved to 28.4% in FY25 from 25.4% in FY24. However, EBITDA margin moderated to 20% in Q2 FY26 (down from 27% YoY) and 22% in H1 FY26 (down from 26% YoY) due to a 7-8x spike in business development and travel expenses.
Capital Expenditure
Net cash outflow for investing activities was INR 27.40 Cr in FY25, primarily directed toward facility modernization and the oncology injectable plant capex. H1 FY26 investing activities totaled INR 27.40 Cr.
Credit Rating & Borrowing
The long-term credit rating has a 'Positive' outlook. Total debt stood at INR 71.86 Cr as of September 2025, with a comfortable Debt-to-Equity ratio of 0.3x in FY25. Interest coverage was reported at 8.95x in H1 FY23.
Operational Drivers
Raw Materials
Oncology Active Pharmaceutical Ingredients (APIs) including Imatinib, and specialized chemicals for formulations. 21 APIs are developed in-house to ensure vertical integration.
Import Sources
Not specifically disclosed, but the company operates an API-integrated unit to reduce external sourcing dependency.
Capacity Expansion
Current operations include an EU GMP-approved oncology oral and injection unit. Capex for an oncology injectable plant is currently in process to reach an optimum scale for the aspirational INR 1,000 Cr revenue target by FY30.
Raw Material Costs
Raw material costs contributed to a 200 bps margin moderation in Q1 FY26. The company uses an API-integrated model (21 in-house APIs) to mitigate price volatility and ensure supply stability.
Manufacturing Efficiency
The company maintains 277 product SKUs and is focusing on higher-margin oncology products to improve blended operating margins, which reached 28.4% in FY25.
Strategic Growth
Expected Growth Rate
57%
Growth Strategy
Growth is driven by a management target of INR 280 Cr for FY26, supported by 49 oncology product agreements and a contract manufacturing deal with Accord Healthcare (signed Feb 2025). The company is leveraging 11 new marketing authorizations (6 in Europe, 5 in Emerging Markets) and has 80+ dossiers pending to trigger export growth in Q4 FY26.
Products & Services
Oncology oral tablets, oncology injections, Active Pharmaceutical Ingredients (APIs) such as Imatinib, and CDMO/CMO services for multinational pharmaceutical companies.
Brand Portfolio
Sakar Healthcare (Own Brand Exports to 60+ countries).
New Products/Services
Received first patent for oncology product Imatinib; R&D is actively developing patent non-infringing products for European partners.
Market Expansion
Expanding footprint in Europe, APAC, Latin America, Africa, and CIS; 80+ dossiers submitted worldwide for new registrations.
Strategic Alliances
Contract manufacturing agreement with Accord Healthcare Limited signed in February 2025 to scale oncology operations.
External Factors
Industry Trends
The industry is shifting toward specialized oncology care. Sakar is positioned for this with an 80% growth in oncology revenue in FY25. EU GMP compliance is a critical industry standard that Sakar has achieved to access European markets.
Competitive Landscape
Competes in the global oncology formulations and CDMO market against both domestic and international pharmaceutical firms.
Competitive Moat
The moat consists of a research-driven, API-integrated oncology unit with EU GMP approval. This high regulatory barrier, combined with 21 in-house APIs and a patent for Imatinib, provides a sustainable cost and compliance advantage.
Consumer Behavior
Rising global demand for affordable oncology treatments is driving the shift toward generic oncology formulations and CDMO services.
Geopolitical Risks
Trade barriers or regulatory changes in the 60+ export countries could impact the 80+ pending dossiers and marketing authorizations.
Regulatory & Governance
Industry Regulations
Strict adherence to EU GMP (European Union Good Manufacturing Practice) and EMA (European Medicines Agency) standards for exports. Compliant with SEBI Listing Regulations 17 to 27.
Taxation Policy Impact
Effective tax rate is approximately 20% based on H1 FY26 figures (PBT of INR 10.74 Cr vs PAT of INR 9.21 Cr).
Legal Contingencies
No material non-compliance or penalties imposed by SEBI or Stock Exchanges in the last three years. Financial statements for FY25 contain no audit qualifications.
Risk Analysis
Key Uncertainties
Execution risk associated with scaling oncology operations to reach the INR 1,000 Cr FY30 target and potential delays in marketing authorizations for the 80+ submitted dossiers.
Geographic Concentration Risk
Revenue is diversified across 60+ countries, reducing single-region dependency.
Third Party Dependencies
Significant dependency on the contract manufacturing agreement with Accord Healthcare Limited for oncology segment growth.
Technology Obsolescence Risk
Mitigated by an active R&D team developing 21 in-house APIs and patent non-infringing products.
Credit & Counterparty Risk
Trade payables increased to INR 36.03 Cr in Sep-25 from INR 21.07 Cr in Sep-24, reflecting increased procurement activity for the oncology scale-up.